|
π
|
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
16 auth.
B. Feagan,
P. Rutgeerts,
B. Sands,
S. Hanauer,
J. Colombel,
W. Sandborn,
G. Van Assche,
J. Axler,
Hyo-Jong Kim,
S. Danese,
...
I. Fox,
C. Milch,
S. Sankoh,
T. Wyant,
Jing Xu,
A. Parikh
|
11 |
2013 |
11
π
|
|
π¬
|
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-Ξ±4Ξ²7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
D. Soler,
T. Chapman,
Lili Yang,
T. Wyant,
R. Egan,
E. Fedyk
|
8 |
2009 |
8
π¬
|
|
π
|
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.
12 auth.
C. Vergunst,
D. Gerlag,
L. Lopatinskaya,
Lars Klareskog,
M. Smith,
F. E. Van den Bosch,
...
H. Dinant,
Yih Lee,
T. Wyant,
E. Jacobson,
D. Baeten,
P. Tak
|
7 |
2008 |
7
π
|
|
π
|
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Doseβranging Study
9 auth.
A. Parikh,
T. Leach,
T. Wyant,
C. Scholz,
S. Sankoh,
D. Mould,
...
T. Ponich,
I. Fox,
B. Feagan
|
7 |
2012 |
7
π
|
|
π¦
|
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
T. Wyant,
E. Fedyk,
B. Abhyankar
|
7 |
2016 |
7
π¦
|
|
π
|
Phase 2 Clinical Trial of AttenuatedSalmonella enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in U.S. Volunteers
14 auth.
C. Tacket,
M. Sztein,
S. Wasserman,
G. Losonsky,
K. Kotloff,
T. Wyant,
J. Nataro,
R. Edelman,
J. Perry,
P. Bedford,
...
David Brown,
S. Chatfield,
G. Dougan,
M. Levine
|
7 |
2000 |
7
π
|
|
π¦
|
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results
8 auth.
T. Wyant,
T. Leach,
S. Sankoh,
Yuemei Wang,
J. Paolino,
M. Pasetti,
...
B. Feagan,
A. Parikh
|
7 |
2014 |
7
π¦
|
|
π
|
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region.
8 auth.
J. Gilbert,
J. Lekstrom-Himes,
D. Donaldson,
Yih Lee,
Mingxiu Hu,
Jing Xu,
...
T. Wyant,
M. Davidson
|
7 |
2011 |
7
π
|
|
π¦
|
Salmonella typhi Flagella Are Potent Inducers of Proinflammatory Cytokine Secretion by Human Monocytes
T. Wyant,
M. Tanner,
M. Sztein
|
7 |
1999 |
7
π¦
|
|
π
|
Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gutβselectivity of this pathway in primates
7 auth.
E. Fedyk,
T. Wyant,
Lili Yang,
V. Csizmadia,
K. Burke,
Hua Yang,
...
V. Kadambi
|
7 |
2012 |
7
π
|
|
π
|
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
8 auth.
M. Rosario,
N. Dirks,
C. Milch,
A. Parikh,
M. Bargfrede,
T. Wyant,
...
E. Fedyk,
I. Fox
|
7 |
2017 |
7
π
|
|
π
|
Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with Salmonella enterica Serovar Typhi Strain CVD 908-htrA 1
7 auth.
R. Salerno-Gonçalves,
T. Wyant,
M. Pasetti,
M. FernΓ‘ndez-ViΓ±a,
C. Tacket,
M. Levine,
...
M. Sztein
|
6 |
2003 |
6
π
|
